Results 11 to 20 of about 1,472 (172)

LC-MS/MS quantification of omadacycline in human plasma for therapeutic drug monitoring: method development and clinical application [PDF]

Scientific Reports
Omadacycline, a third-generation tetracycline antibiotic, exhibits time-dependent pharmacokinetics. The ratio of the 24-hour area under the concentration-time curve to minimum inhibitory concentration (AUC0−24/MIC) serves as the primary pharmacokinetic ...
Yueyuan Wang, Zhipeng Diao, Yuchen Qu, Kai Fan, Chen Feng, Bo Lv, Yunli Yu, Zhou Geng   +7 more
doaj   +2 more sources

Clinical Efficacy and Safety of Omadacycline Versus Tigecycline in Treating Severe Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacilli: A Retrospective Cohort Study [PDF]

Infection and Drug Resistance
Ye Zhang,1 Fei Wang,2 Min Wang,1 Wenhui Xu,3 Aiping Wang,3 Yueping Ding2 1Department of Pharmacy, The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Intensive Care Unit ...
Zhang Y, Wang F, Wang M, Xu W, Wang A, Ding Y   +5 more
doaj   +2 more sources

Activity of omadacycline in vitro against Clostridioides difficile and preliminary efficacy assessment in a hamster model of C. difficile-associated diarrhoea

Journal of Global Antimicrobial Resistance, 2022
: Objectives: Antibiotics are associated with increased risk of Clostridioides difficile infection, which has limited treatment options. We assessed in vitro activity of omadacycline (an aminomethylcycline antibiotic) against the C.
Raina Gay Leahy, Alisa W. Serio, Kelly Wright, Maria M. Traczewski, S. Ken Tanaka   +4 more
doaj   +1 more source

Omadacycline Is Highly Active In Vitro against Mycoplasma genitalium

Microbiology Spectrum, 2022
Here, we performed in vitro susceptibility testing on 10 Mycoplasma genitalium isolates against omadacycline, minocycline, tetracycline, doxycycline, moxifloxacin, levofloxacin, and azithromycin.
Ken B. Waites, Donna M. Crabb, T. Prescott Atkinson, William M. Geisler, Li Xiao   +4 more
doaj   +1 more source

Omadacycline for treatment of acute bacterial infections: a meta-analysis of phase II/III trials

BMC Infectious Diseases, 2023
Objective This study aims to assess the clinical efficacy and safety of omadacycline for the treatment of acute bacterial infections. Methods A search of PubMed, Embase, Cochrane Library, and Clinical Trials was conducted up to July 1, 2022.
Fei Lin, Rong He, Bin Yu, Bowen Deng, Baodong Ling, Mingyong Yuan   +5 more
doaj   +1 more source

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects

Frontiers in Pharmacology, 2022
Objective: Omadacycline is a new type of aminomethylcycline antibiotic, having a broad antibacterial spectrum. But the pharmacokinetic characteristics and safety profile of the Chinese population remain unknown. It is also unclear whether the US-approved
Haijing Yang, Haijing Yang, Haijing Yang, Zhiwei Huang, Zhiwei Huang, Zhiwei Huang, Yuancheng Chen, Yuancheng Chen, Yuancheng Chen, Yusong Zhu, Guoying Cao, Guoying Cao, Guoying Cao, Jingjing Wang, Jingjing Wang, Jingjing Wang, Yan Guo, Yan Guo, Yan Guo, Jicheng Yu, Jicheng Yu, Jicheng Yu, Jufang Wu, Jufang Wu, Jufang Wu, Lichuan Liu, Jun Deng, Jing Liu, Harald Reinhart, Jing Zhang, Jing Zhang, Jing Zhang, Xiaojie Wu, Xiaojie Wu, Xiaojie Wu   +34 more
doaj   +1 more source

In Vitro Activity of Omadacycline and Comparator Antibiotics against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Urinary Isolates

Antibiotics, 2023
Limited oral antibiotic options exist for urinary tract infections (UTI) caused by ESBL-producing Enterobacterales. The aim of the study was to evaluate in vitro activity of omadacycline and comparator antibiotics against clinical ESBL-producing and non ...
Tyler J. Stone, Abdullah Kilic, John C. Williamson, Elizabeth L. Palavecino   +3 more
doaj   +1 more source

In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden

Microbiology Spectrum, 2021
Clostridioides difficile infection represents a growing clinical challenge. The new compound omadacycline is a potential treatment alternative, as many antibiotics have limited activity or are rarely used due to costs and side effects.
Angela Camporeale, Chaitanya Tellapragada, Jelena Kornijenko, Carl Erik Nord, Christian G. Giske   +4 more
doaj   +1 more source

Investigating the immunomodulatory activities of omadacycline

Journal of Antimicrobial Chemotherapy, 2022
Abstract Background Apart from their antimicrobial activities, some antibiotics have immunomodulatory effects on host cells, particularly monocytes. Because hyperactivation of the pro-inflammatory cytokine response contributes to acute lung injury in patients with bacterial pneumonia and other lung ...
Bryant, Amy E, Stevens, Dennis L
openaire   +2 more sources

Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study

BMC Microbiology, 2020
Background Omadacycline (ZL-2401) is a semi-synthetic derivative of minocycline. It has a broadspectrum activity against Gram-positive and Gram-negative bacteria, and atypical pathogens.
Meng Xiao, Jing-jing Huang, Ge Zhang, Wen-hang Yang, Fanrong Kong, Timothy Kudinha, Ying-chun Xu   +6 more
doaj   +1 more source